Adel El Abbassi, MD
Pulmonary Disease · Abingdon, VANPI 1437346301
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Intuitive Surgical at 28.6% of the total. Reporting peaked in 2024 at $8,269 and has fallen 67.0% since, to $2,725 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 605 payments — averaging $41.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$3K
- Pinnacle Biologics, Inc$2K
- GSK$2K
- Covidien LP$1K
- Olympus Corporation Of The Americas$1K
- plus $7K from 35 others
What the payments were for
- Speaking & faculty fees$1,2005%
- Travel & lodging$5,62923%
- Food & beverage$13,97256%
- Education$4,08616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $7,123 |
| AstraZeneca | 114 | $3,345 |
| Pinnacle Biologics, Inc | 11 | $2,334 |
| GSK | 141 | $2,194 |
| Covidien LP | 9 | $1,467 |
| Olympus Corporation Of The Americas | 10 | $1,124 |
| Regeneron Healthcare Solutions, Inc. | 32 | $929 |
| Actelion Pharmaceuticals US, Inc. | 40 | $906 |
| Boehringer Ingelheim | 29 | $503 |
| Grifols USA, LLC | 21 | $454 |
| Mallinckrodt Hospital Products Inc. | 20 | $452 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $403 |
| Sanofi | 16 | $389 |
| Johnson & Johnson(2 entities) | 5 | $326 |
| Amgen | 20 | $321 |
| United Therapeutics Corporation | 9 | $266 |
| Merck | 10 | $251 |
| Insmed, Inc. | 11 | $247 |
| CSA Medical, Inc | 1 | $214 |
| Mylan Specialty L.p. | 12 | $172 |
| Jazz Pharmaceuticals Inc. | 5 | $171 |
| Mallinckrodt Enterprises LLC | 6 | $161 |
| Baxter Healthcare | 7 | $156 |
| La Jolla Pharmaceutical Company | 6 | $149 |
| Genentech USA, Inc. | 7 | $114 |
| AbbVie | 1 | $91 |
| Pulmonx Corporation | 3 | $88 |
| Circassia Inc. | 5 | $67 |
| Inogen, Inc. | 3 | $63 |
| Novartis | 3 | $58 |
| Verona Pharma, Inc. | 3 | $57 |
| Pfizer | 3 | $47 |
| Electromed, Inc. | 2 | $43 |
| Viatris Specialty LLC | 2 | $41 |
| Philips North America LLC | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Resmed Corp | 1 | $21 |
| Medtronic | 1 | $21 |
| Olympus America Inc. | 1 | $20 |
| Shionogi Inc | 1 | $19 |
| Harmony Biosciences LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,969
- Photofrin$1,824
- superDimension$1,199
- Olympus Bronchoscopes$992
- Olympus Capital Accessories$992
- Olympus Respiratory Accessories$992
- MONARCH$283
- DUPIXENT$135
- FASENRA$127
- NUCALA$125
- AIRSUPRA$125
- BREZTRI AEROSPHERE$118
- XYREM$100
How this compares
$24,886 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 18 | $77,044 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,233 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,093 |
| Spiriva RespimatTiotropium Bromide | 18 | $10,288 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $517 |
| Prednisone | 23 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta | $2,194 | $96,27743 claims |
| AstraZenecaBreztri Aerosphere | $3,345 | $12,09320 claims |
| Boehringer IngelheimSpiriva Respimat | $503 | $10,28818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Abingdon
- Robert JonesAbingdon$12K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.